Billerica, Massachusetts, April 27, 2016 —MilliporeSigma is launching three Mobius® products that deliver improved efficiency and ease-of-use for biopharmaceutical manufacturing workflows.
The new Mobius® products include a 1000-liter single-use bioreactor with an industry-leading design, a 2000-liter mixing system for difficult-to-mix biopharm ingredients and a large volume liquid transport system for aseptic and non-aseptic substances.
“Our newest Mobius® products meet our customers’ increasingly complex demands for user friendly systems that allow them to focus on their science,” said Udit Batra, CEO, MilliporeSigma.
The Mobius® 1000 liter single-use bioreactor completes the comprehensive Mobius® stirred tank portfolio of 3 to 2000 liter sizes, delivering greater flexibility and continuity for scale-up. With the industry’s only bottom-loading drawer for easy and safe bag installation, MilliporeSigma’s new bioreactor is designed to achieve homogenous and fast mixing for consistent performance, especially at large scale.
The Mobius® Power MIX 2000 creates a strong vortex to handle difficult-to-mix buffers, media and other biopharm ingredients. Powerful mixing is achieved from an impeller design and motor based on magnetically-coupled NovAseptic® technology, a proven mixing technology in stainless steel tanks. The Power MIX 2000 provides accessible, sterile zero deadleg sampling directly from the mixing container. A Probe Port allows for insertion of either a reusable probe for non-aseptic processes or a pre-sterilized, single-use sensor for in-process pH measurement of aseptic processes.
The Mobius® single-use 3D large liquid transportation system’s single-use bags and stainless steel transporter bins facilitate the safe and convenient road transport of aseptic and non-aseptic media, buffers, in-process intermediates and final bulk drug products at cold or ambient temperatures. The system offers four single-use bag assemblies with working volumes of 100 to 500 liters. All bags are constructed from PureFlex™ Plus film with a proven low extractable profile and gas barrier properties.
MilliporeSigma will showcase its industry-leading portfolio of single-use and other biopharmaceutical manufacturing products at booth #2841 at INTERPHEX 2016 in New York City from April 26 – 28. Follow us on Twitter: @MilliporeSigma.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 72 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $130 billion global life science industry.
Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of €12.85 billion in 2015. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.
Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany operates as EMD Serono, MilliporeSigma and EMD Performance Materials in the U.S. and Canada.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.